单位：[1]Falk Brain Tumor Center, Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA[2]Development Biology Program, Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA[3]Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, USA外科学系神经外科[4]Department of Biological Sciences, Purdue University Calumet, Hammond, USA[5]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China神经外科外科学系
Patients with brain tumors, specificaly, malignant forms such as glioblastoma, meduloblas-toma and ependymoma, exhibit dismal survival rates despite advances in treatment strategies. Chemotherapeutics, the primary adjuvant treatment for human brain tumors folowing surgery, commonly lack eficacy due to either intrinsic or acquired drug resistance. New treatments tar-geting epigenetic factors are being explored. Post-translational histone modification provides a critical regulatory platform for processes such as chromosome condensation and segregation, apoptosis, gene transcription, and DNA replication and repair. This work reviews how aberrant histone modifications and alterations in histone-modifying enzymes can drive the acquisition of drug resistance in brain tumors. Elucidating these mechanisms should lead to new treatments for overcoming drug resistance.
基金：
the Rory David Deutsch Foundation, the Surgical Neuro-oncology Research Fund of Ann & Robert H Lurie Children’s Hospi-tal (A&RLCH) of Chicago, and the Dr. Ralph and Marian C. Falk Medical Research Trust
语种：
外文
第一作者：
第一作者单位：[1]Falk Brain Tumor Center, Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA[2]Development Biology Program, Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA[3]Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, USA
通讯作者：
推荐引用方式(GB/T 7714)：
Guifa Xi,Barbara Mania-Farnell,Ting Lei,et al.Histone modification as a drug resistance driver in brain tumors[J].肿瘤学与转化医学（英文）.2016,2(5):216-226.doi:10.1007/s10330-016-0165-5.
APA：
Guifa Xi,Barbara Mania-Farnell,Ting Lei&Tadanori Tomita.(2016).Histone modification as a drug resistance driver in brain tumors.肿瘤学与转化医学（英文）,2,(5)
MLA：
Guifa Xi,et al."Histone modification as a drug resistance driver in brain tumors".肿瘤学与转化医学（英文） 2..5(2016):216-226
